
    
      This is a double-blind, randomized, placebo-controlled, multiple-dose, two-center, safety and
      efficacy study of co-administration of tesofensine/metoprolol treatment in subjects with
      T2DM. Study medication will be administered for ninety (90) days (+2 days after the final
      assessments with half-dose of metoprolol). Following all baseline assessments, eligible
      subjects will be randomly assigned to one of the two arms (1:1).
    
  